Valneva's 15-minute chart exhibits bearish MACD Death Cross, Marubozu formation.

Valneva's 15-minute chart exhibits a MACD Death Cross and a Bearish Marubozu at 10/09/2025 13:15. This indicates a potential continuation of the downward trend, with sellers dominating the market and bearish momentum likely to persist.

Valneva's (VLA) shares have taken a significant tumble, falling by 7% on September 10, 2025, following the announcement of a delay in the release of Phase 3 Lyme disease vaccine data and a downward revision of its 2025 financial outlook. The French biopharmaceutical company has postponed the release of the critical data to the first half of 2026, a delay that has sparked investor concern Valneva falls after Lyme disease vaccine data delay, outlook cut^[1].

Analysts initially expected the Phase 3 data to be released by the end of 2025. The delay, coupled with a reduction in revenue projections and research and development (R&D) investments, has led to a substantial sell-off in Valneva's stock. The company now anticipates annual revenue of €165-180 million ($193-210 million) for 2025, down from the previously projected €180-190 million. Additionally, R&D investments are expected to fall to €80-90 million from the previously planned €90-100 million Valneva falls after Lyme disease vaccine data delay, outlook cut^[1].

The delayed data release and reduced guidance have contributed to a bearish market sentiment, with Valneva's shares on track for their worst performance in six weeks. The technical indicators, including a MACD Death Cross and a Bearish Marubozu on the 15-minute chart at 13:15 on September 10, 2025, further suggest a potential continuation of the downward trend, indicating strong selling pressure and bearish momentum .

Investors and financial professionals should closely monitor Valneva's upcoming earnings reports and any updates on the Phase 3 data to gauge the potential impact on the company's stock price and overall market performance.